Malignant Supratentorial Neoplasm
Associated Genetic Biomarkers
There are 4 clinical trials for malignant supratentorial neoplasm, of which 4 are open and 0 are completed or closed. Of the trials that contain malignant supratentorial neoplasm as an inclusion criterion, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 2 are phase 2 (2 open).
EGFR is the most frequent gene inclusion criterion for malignant supratentorial neoplasm clinical trials .
Temozolomide, autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine, and autologous cmv-pp65-shlamp-1 mrna loaded dendritic cell vaccine are the most common interventions in malignant supratentorial neoplasm clinical trials.
Significant Genes in Malignant Supratentorial Neoplasm
EGFR is an inclusion eligibility criterion in 1 clinical trial for malignant supratentorial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant supratentorial neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.